| Name | Title | Contact Details |
|---|
Angel Care Home Health Care is a Grand Rapids, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Episcopal Health Services (EHS) traces its roots almost 150 years back to the Church Charity Foundation which was founded on February 6, 1851 for aged indigent persons and for the welfare of orphans, half orphans, and other destitute children.
Pinetree is a diversified investment, financial advisory and venture capital firm focused on investing in early stage micro and small cap resource companies. Pinetree`s investments are primarily in the following resource sectors: Precious Metals, Base Metals Oil and Gas, Potash, Lithium and Rare Earths, Uranium and Coal. Pinetree`s investment approach is to develop a macro view of a sector, build a position consistent with the view by identifying micro-cap opportunities within that sector and devise an exit strategy designed to maximize our relative return in light of changing fundamentals and opportunities. Pinetree is recognized as a value added partner in the resource industry.
With personalized treatments and guidance from medical and athletic professionals, you can achieve your health and fitness goals at Altus.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.